» Articles » PMID: 9440119

Lipopolysaccharide-induced Cytokine Cascade and Lethality in LT Alpha/TNF Alpha-deficient Mice

Overview
Journal Mol Med
Publisher Biomed Central
Date 1998 Jan 24
PMID 9440119
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tumor necrosis factor alpha (TNF-alpha) is often considered the main proinflammatory cytokine induced by lipopolysaccharide (LPS) and consequently the critical mediator of the lethality associated with septic shock.

Materials And Methods: We used mice carrying a deletion of both the lymphotoxin alpha (LT-alpha) and TNF-alpha genes to assess the role of TNF in the cytokine cascade and lethality induced by LPS.

Results: Initial production of IL-1 alpha, IL-1 beta, IL-6, and IL-10 is comparable in wild-type and mutant mice. However, at later times, expression of IL-1 alpha, IL-1 beta, and IL-10 is prolonged, whereas that of IL-6 decreases in mutant mice. Expression of IFN-gamma is almost completely abrogated in mutants, which is in agreement with a more significant alteration of the late phase of the cytokine cascade. We measured similar LD50 (600 micrograms) for the intravenous injection of LPS in mice of the three genotypes (+/+, +/-, -/-), demonstrating that the absence of TNF does not confer long-term protection from lethality. However, death occurred much more slowly in mutant mice, who were protected more efficiently from death by CNI 1493, an inhibitor of proinflammatory cytokine production, than were wild-type mice.

Discussion: Thus, while TNF-alpha is not required for the induction of these cytokines by LPS, it modulates the kinetics of their expression. The lethality studies simultaneously confirm a role for TNF as a mediator of early lethality and establish that, in the absence of these cytokines, other mediators take over, resulting in the absence of long-term protection from LPS toxicity.

Citing Articles

Dual alarmin-receptor-specific targeting peptide systems for treatment of sepsis.

Mun S, Cho E, Gil W, Kim S, Kim H, Ham Y Acta Pharm Sin B. 2025; 14(12):5451-5463.

PMID: 39807314 PMC: 11725134. DOI: 10.1016/j.apsb.2024.08.015.


Divergent effects of tumor necrosis factor (TNF) in sepsis: a meta-analysis of experimental studies.

Kassasseya C, Torsin L, Musset C, Benhamou M, Chaudry I, Cavaillon J Crit Care. 2024; 28(1):293.

PMID: 39227889 PMC: 11373197. DOI: 10.1186/s13054-024-05057-0.


Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis.

Freeze R, Yang K, Haystead T, Hughes P, Scarneo S Pharmacol Res Perspect. 2023; 11(4):e01124.

PMID: 37564034 PMC: 10415874. DOI: 10.1002/prp2.1124.


Cooperation between CYB5R3 and NOX4 via coenzyme Q mitigates endothelial inflammation.

Yuan S, Hahn S, Miller M, Sanker S, Calderon M, Sullivan M Redox Biol. 2021; 47:102166.

PMID: 34656824 PMC: 8577475. DOI: 10.1016/j.redox.2021.102166.


Growth differentiation factor 15 neutralization does not impact anorexia or survival in lipopolysaccharide-induced inflammation.

Breen D, Jagarlapudi S, Patel A, Zou C, Joaquim S, Li X iScience. 2021; 24(6):102554.

PMID: 34189431 PMC: 8215224. DOI: 10.1016/j.isci.2021.102554.


References
1.
Erickson S, de Sauvage F, Kikly K, Gillett N, Sheehan K, Schreiber R . Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994; 372(6506):560-3. DOI: 10.1038/372560a0. View

2.
Netea M, Blok W, Kullberg B, Bemelmans M, Vogels M, Buurman W . Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis. 1995; 171(2):393-9. DOI: 10.1093/infdis/171.2.393. View

3.
Abraham E, Wunderink R, Silverman H, Perl T, Nasraway S, Levy H . Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995; 273(12):934-41. View

4.
Junger W, Hoyt D, Redl H, Liu F, Loomis W, Davies J . Tumor necrosis factor antibody treatment of septic baboons reduces the production of sustained T-cell suppressive factors. Shock. 1995; 3(3):173-8. DOI: 10.1097/00024382-199503000-00003. View

5.
Sower L, Froelich C, Carney D, Fenton 2nd J, Klimpel G . Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol. 1995; 155(2):895-901. View